Trulicity (dulaglutide) is a once-weekly injectable medication for type 2 diabetes manufactured by Eli Lilly. It belongs to the GLP-1 receptor agonist class, lowers A1C by 0.7 to 1.5 percentage points, modestly reduces body weight, and lowers the risk of cardiovascular events in adults with type 2 diabetes and cardiovascular risk factors (REWIND trial). It is delivered by a single-dose auto-injector with a hidden needle, which many patients find simpler than multi-step insulin pens.
What Trulicity Is Approved For
FDA indications:
- Improvement of glycemic control in adults with type 2 diabetes, as an adjunct to diet and exercise
- Same indication extended to children 10 years and older with type 2 diabetes
- Reduction of major adverse cardiovascular events (cardiovascular death, non-fatal MI, non-fatal stroke) in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors
Trulicity is not FDA-approved for chronic weight management. Semaglutide 2.4 mg (Wegovy) and tirzepatide (Zepbound) are the GLP-1 class drugs approved specifically for obesity in the United States.
How Trulicity Works
Dulaglutide is a modified GLP-1 molecule joined to a fragment of human IgG4 Fc, which extends its half-life to about 5 days and allows once-weekly dosing. It activates the GLP-1 receptor at multiple sites:
- Pancreas: stimulates glucose-dependent insulin release; suppresses glucagon
- Stomach: slows gastric emptying, smoothing the post-meal glucose curve
- Brain: increases satiety and reduces appetite
- Cardiovascular system: modest reduction in blood pressure and favorable effects on lipid metabolism
Dosing Schedule
| Dose | When | Role |
|---|---|---|
| 0.75 mg weekly | Weeks 1 to 4 | Starting dose — partial effect; allows gut to adapt |
| 1.5 mg weekly | Week 5 onward | Primary effective dose for most adults |
| 3 mg weekly | Step up after 4 weeks on 1.5 mg | Used when further A1C lowering needed |
| 4.5 mg weekly | Step up after 4 weeks on 3 mg | Maximum dose |
How Effective Is Trulicity?
| Metric | 1.5 mg | 3 mg | 4.5 mg |
|---|---|---|---|
| A1C reduction | -1.0 to -1.1% | -1.3 to -1.5% | -1.5 to -1.8% |
| Weight change at 40-52 wk | -2 to -3 kg | -3 to -4 kg | -4 to -5 kg |
| Patients reaching A1C under 7% | ~50 to 60% | ~60 to 70% | ~65 to 75% |
Cardiovascular Benefit
The REWIND trial (2019) enrolled over 9,900 adults with type 2 diabetes and either established cardiovascular disease or multiple cardiovascular risk factors. At median 5.4 years of follow-up, dulaglutide reduced the composite of cardiovascular death, non-fatal MI, and non-fatal stroke by 12 percent. Stroke reduction was the strongest component. This data supports the FDA-approved cardiovascular indication for appropriate patients.
Common Side Effects
| Side Effect | Approx Incidence | Notes |
|---|---|---|
| Nausea | 12 to 21% | Most common; peaks after each dose step |
| Diarrhea | 8 to 13% | Usually mild to moderate |
| Vomiting | 6 to 14% | When nausea is severe |
| Abdominal pain | 6 to 9% | Mild, cramp-like |
| Decreased appetite | 5 to 9% | Often welcomed by patients with weight goals |
| Fatigue | 4 to 5% | |
| Injection-site reaction | 1 to 2% | Usually mild redness or small bump |
Most GI side effects improve within 2 to 4 weeks as the gut adapts to slower emptying.
Serious Warnings and Contraindications
- Boxed warning — thyroid C-cell tumors: seen in rodents; contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN 2).
- Pancreatitis: severe, persistent abdominal pain radiating to the back — stop the drug and evaluate.
- Gallbladder disease: right-upper-quadrant pain, fever, jaundice — stop and evaluate.
- Acute kidney injury: dehydration from vomiting or diarrhea can worsen kidney function; hold the drug during illness.
- Diabetic retinopathy: rapid glucose improvements can transiently worsen retinopathy; baseline dilated exam recommended.
- Hypoglycemia: low on Trulicity alone, but significant when combined with insulin or sulfonylureas.
- Hypersensitivity reactions: rare; any hives, facial swelling, or breathing difficulty requires emergency care.
Drug Interactions to Know
- Warfarin: monitor INR more frequently when starting.
- Oral contraceptives and time-sensitive oral drugs: slowed gastric emptying may delay absorption; take at consistent times.
- Insulin and sulfonylureas: reduce dose to avoid hypoglycemia.
Storage and Administration
- Store unused pens refrigerated at 36°F to 46°F (2°C to 8°C).
- Do not freeze. Discard any frozen pen.
- A pen can be kept at room temperature (up to 86°F / 30°C) for up to 14 days.
- Rotate injection sites weekly: abdomen (at least 2 inches from belly button), front of thigh, or upper arm (if someone else injects).
- The pen delivers a fixed dose with a press-and-hold motion; expect two audible clicks (insertion and completion).
For the full injection walkthrough, see our companion guide on the Trulicity injection.
How Trulicity Compares to Other GLP-1 Drugs
| Drug | Class | Frequency | A1C Reduction | Weight Loss |
|---|---|---|---|---|
| Trulicity (dulaglutide) | GLP-1 | Weekly | -0.7 to -1.8% | -2 to -5 kg |
| Ozempic (semaglutide) | GLP-1 | Weekly | -1.0 to -2.0% | -4 to -6 kg |
| Mounjaro (tirzepatide) | GLP-1/GIP | Weekly | -1.5 to -2.5% | -6 to -12 kg |
| Victoza (liraglutide) | GLP-1 | Daily | -1.0 to -1.5% | -2 to -3 kg |
| Byetta (exenatide) | GLP-1 | Twice daily | -0.8 to -1.0% | -2 to -3 kg |
Cost and Insurance
Trulicity’s US list price is in the $900 to $1,000 per month range, though commercial insurance typically reduces out-of-pocket cost substantially. Eli Lilly’s patient savings card reduces copays for commercially insured patients; Lilly Cares provides free medication for qualifying uninsured or underinsured patients. Generic dulaglutide is not yet available.
Related Reading
For broader context on how GLP-1 therapy fits into diabetes care, see our treatment hub. Trulicity, Ozempic, Mounjaro, and Wegovy all work through related mechanisms — our A1C levels guide covers the target ranges these drugs help you reach.
The Bottom Line
Trulicity is a proven once-weekly GLP-1 medication for adults and children 10+ with type 2 diabetes. It lowers A1C by 0.7 to 1.8 percentage points, produces modest weight loss, reduces cardiovascular events in at-risk adults, and uses a simple hidden-needle auto-injector. Side effects are mostly GI and mostly temporary; serious warnings are uncommon but real. For many patients it is a reasonable second-line option after metformin — discuss specific fit and cost with your clinician.
